245,587 Shares in Kyverna Therapeutics, Inc. $KYTX Acquired by Walleye Capital LLC

Walleye Capital LLC acquired a new position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 245,587 shares of the company’s stock, valued at approximately $2,188,000.

Other large investors have also recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio bought a new stake in Kyverna Therapeutics during the 3rd quarter valued at $28,000. Federated Hermes Inc. grew its stake in shares of Kyverna Therapeutics by 36.6% in the fourth quarter. Federated Hermes Inc. now owns 20,705 shares of the company’s stock worth $195,000 after purchasing an additional 5,547 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Kyverna Therapeutics by 22.0% in the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after purchasing an additional 5,694 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Kyverna Therapeutics by 41.6% in the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after purchasing an additional 6,400 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Kyverna Therapeutics by 0.8% during the third quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company’s stock valued at $7,936,000 after purchasing an additional 9,858 shares during the period. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently weighed in on KYTX. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Wednesday, June 24th. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Kyverna Therapeutics in a research report on Wednesday, June 3rd. JPMorgan Chase & Co. lowered their target price on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Finally, Wall Street Zen downgraded shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $30.00.

Key Kyverna Therapeutics News

Here are the key news stories impacting Kyverna Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its estimates across multiple periods, including FY2026 EPS to a loss of $2.70 from $2.98 and FY2027 EPS to a loss of $2.79 from $3.01. The firm maintained a Buy rating and a $25 price target, implying substantial upside from recent trading levels. MarketBeat Kyverna Therapeutics analyst estimates
• Positive Sentiment: The revised forecasts also improved expected quarterly results for Q3 and Q4 2026 and Q1 through Q4 2027, suggesting HC Wainwright sees a better earnings trajectory, although KYTX is still expected to remain unprofitable. The company recently beat quarterly EPS expectations, reporting a $0.63 loss versus the $0.68 consensus loss.
• Positive Sentiment: Kyverna’s reported progress toward potential approval supports the long-term investment case because successful regulatory advancement could improve the prospects for its cell-therapy platform. Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval
• Neutral Sentiment: Despite the favorable HC Wainwright view, broader analyst opinions on KYTX remain mixed. That lack of consensus likely limited the stock’s reaction to the improved estimates and approval-related progress. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Negative Sentiment: Kyverna remains a development-stage biotechnology company with substantial expected losses, making the stock highly dependent on clinical, regulatory and financing progress. Its beta of 1.93 also indicates elevated volatility.

Kyverna Therapeutics Price Performance

NASDAQ:KYTX opened at $8.17 on Friday. The company has a quick ratio of 8.15, a current ratio of 9.06 and a debt-to-equity ratio of 0.15. The business’s 50-day moving average price is $8.07 and its 200 day moving average price is $8.43. Kyverna Therapeutics, Inc. has a 52-week low of $3.27 and a 52-week high of $13.67. The firm has a market cap of $505.26 million, a P/E ratio of -2.78 and a beta of 1.93.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.05. As a group, sell-side analysts predict that Kyverna Therapeutics, Inc. will post -2.7 earnings per share for the current fiscal year.

Kyverna Therapeutics Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.